Table 1.
Demographic and baseline clinical characteristics of study participants.
| Characteristic | First-line ART | Second-line ART | Total, n (%) |
|---|---|---|---|
| Value | |||
| Total no. of participants – n (%) | 43 (45.7) | 51 (54.3) | 94 (100) |
| Female – n (%) | 26 (60.5) | 37 (72.5) | 63 (67) |
| Male – n (%) | 17 (39.5) | 14 (27.5) | 31 (33) |
| On LPV/r + TDF/3TC – n (%) | 0 | 7 (13.7) | 7 (7.4) |
| On ATV/r + TDF/3TC – n (%) | 0 | 44 (86.3) | 44 (46.8) |
| On DTG/ TDF/3TC – n (%) | 41 (95.3) | 0 | 41 (43.6) |
| On EFV/ TDF/3TC – n (%) | 2 (4.7) | 0 | 2 (2.1) |
| Viral load ≤ 1000 copies/L – n (%) | 40 (93.0) | 48 (94.1) | 88 (93.6) |
| Viral load > 1000 copies/L – n (%) | 3 (7.0) | 3 (5.9) | 6 (6.4) |
| Mean age -year ± (SD) | 39.8 ± (13.0) | 45 ± (8.2) | 43.9 ± (12.32) |
3TC = Lamivudine, ATV/r = Atazanavir (boosted with ritonavir), DTG = Dolutegravir, EFV = Efavirenz, LPV/r = Lopinavir (boosted with ritonavir), SD = Standard deviation.